Trials / Active Not Recruiting
Active Not RecruitingNCT05558982
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Georgetown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Single-arm, open label study to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in the second-line metastatic setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BXCL701 | BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days |
| DRUG | Pembrolizumab | Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days. |
Timeline
- Start date
- 2023-08-16
- Primary completion
- 2025-12-31
- Completion
- 2027-11-01
- First posted
- 2022-09-29
- Last updated
- 2026-02-12
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05558982. Inclusion in this directory is not an endorsement.